A5018416880- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Food Allergy and Anaphylaxis Research
- Hidradenitis Suppurativa and Treatments
- Colorectal and Anal Carcinomas
- IL-33, ST2, and ILC Pathways
- Autoimmune Bullous Skin Diseases
- Health Systems, Economic Evaluations, Quality of Life
- Contact Dermatitis and Allergies
- Pharmaceutical studies and practices
- Autoimmune and Inflammatory Disorders
- Pharmacological Effects of Natural Compounds
- Acne and Rosacea Treatments and Effects
- T-cell and B-cell Immunology
- Transgenic Plants and Applications
- Drug-Induced Adverse Reactions
- Immunodeficiency and Autoimmune Disorders
- Nail Diseases and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Chemotherapy-related skin toxicity
- Mast cells and histamine
King's College London
2016-2025
Guy's and St Thomas' NHS Foundation Trust
2016-2025
St John's Hospital
2019-2024
St. Luke's Hospital
2024
Center for Clinical Studies
2024
Guy's Hospital
2011-2024
University of Bradford
2024
St Thomas' Hospital
2018-2024
St. John's School
2023
St. Thomas Hospital
2021
The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Data from trials comparing JAK1 inhibitors with monoclonal antibodies, such as dupilumab, that block receptors are limited.In a phase 3, double-blind trial, we randomly assigned patients dermatitis was unresponsive to topical agents or warranted systemic therapy (in 2:2:2:1 ratio) receive 200 mg 100 abrocitinib orally...
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, key driver of atopic dermatitis (AD).To evaluate the efficacy and safety tralokinumab in combination with topical corticosteroids (TCS) patients moderate-to-severe AD who were candidates for systemic therapy.This was double-blind, placebo plus TCS controlled phase III trial. Patients randomized 2 : 1 to subcutaneous 300 mg or every weeks (Q2W) as needed over 16 weeks. achieved an Investigator's...
Importance Generalized pustular psoriasis (GPP) lacks internationally accepted definitions and diagnostic criteria, impeding timely diagnosis treatment hindering cross-regional clinical epidemiological study comparisons. Objective To develop an international consensus definition criteria for GPP using the modified Delphi method. Evidence Review The rarity of presents a challenge in acquiring comprehensive published data necessary developing standardized criteria. Instead relying on...
Linked Comment:Jemec. Br J Dermatol 2019; 180:975. Plain language summary available online
Currently no treat-to-target framework to guide systemic treatment in adults with moderate-to-severe atopic dermatitis exists. We sought reach international consensus through an eDelphi process on a core set of recommendations for such approach. Recommendations were developed by Steering Committee, spanning 3 areas (Guiding Principles, Decision Making, and Outcome Thresholds) 2 specific time-points; initial acceptable target at months optimal 6 months, each based improvements patient global...
Patients with severe atopic dermatitis (AD) not controlled topical therapy have limited treatment options. Ciclosporin A (CSA) is a commonly used, broad immunosuppressant in AD, but CSA requires monitoring for potentially serious adverse effects. In previous phase III trial, tralokinumab plus corticosteroids (TCS) as needed provided early and sustained improvements AD signs symptoms.To evaluate the efficacy safety of TCS adult patients whose disease was adequately or who had...
Additional long-term treatments are needed for moderate-to-severe atopic dermatitis (AD). An ongoing, open-label, 5-year extension trial, ECZTEND (NCT03587805), assesses tralokinumab plus optional topical corticosteroids in participants from previous parent trials (PTs) with AD.To evaluate the safety and efficacy of up to 2 years treatment a post hoc interim analysis.Safety analyses included adults completed PTs enrolled ECZTEND, regardless exposure duration. Efficacy adult treated ≥1 year...
Palmoplantar pustulosis (PPP) is a severe inflammatory skin disorder characterized by eruptions of painful, neutrophil-filled pustules on the palms and soles. Although PPP has profound effect quality life, it remains poorly understood notoriously difficult to treat.We sought investigate immune pathways that underlie pathogenesis PPP.We applied bulk single-cell RNA sequencing (RNA-Seq) methods analysis biopsy samples peripheral blood mononuclear cells. We validated our results flow cytometry...
Abstract Background Current treat‐to‐target recommendations for atopic dermatitis (AD) may not include high enough treatment targets and do fully consider patient needs. Objective To develop optimized AD management, including disease severity assessments, goals targets, guidance escalation/modification. Methods An international group of expert dermatologists drafted a series management using insights from global study 87 44 countries. Experts voted on modified eDelphi voting process. Results...
Abstract Background Cross‐sectional data on patient burden in adults with atopic dermatitis ( AD ) from real‐world clinical practice are limited. Objective This study compared patient‐reported associated adult across severity levels practices Canada and Europe. Methods included (18–65 years) diagnosed by dermatologists, general practitioners or allergists. Participants categorized as mild n = 547; 37.3%), moderate 520; 35.4%) severe 400; 27.3%) based Investigator's Global Assessment...
Topical therapies have been available for the treatment of psoriasis several decades. Despite this and availability types topicals, with varying potency, numerous vehicles administration, majority clinical data guidance is on short-term use in management psoriasis. The aim manuscript to review unmet needs that exist long-term provide dermatology community an understanding a regimen topical could be best option at least some phases chronic relapsing disease. We present 'call action' need...
The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated patients achieved primary endpoints Investigator's Global Assessment (IGA) score 0/1 75% improvement Eczema Area Severity Index (EASI-75) all confirmatory at Week 16. This post hoc analysis investigated impact...
Journal Article Antinuclear antibodies associate with loss of response to antitumour necrosis factor‐α therapy in psoriasis: a retrospective, observational study Get access A.E. Pink, Pink St John's Institute Dermatology, Guy's and Thomas' NHS Foundation Trust Division Genetics Molecular Medicine, King's College London, 9th Floor Tower, Great Maze Pond, London SE1 9RT, U.K. Search for other works by this author on: Oxford Academic Google Scholar A. Fonia, Fonia M.H. Allen, Allen C.H. Smith,...